Akari Therapeutics, Plc Interest Expense 2011-2026 | AKTX

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Akari Therapeutics, Plc

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
100 K	-3 K	-19 K	368 K	-	-	-	-	-	-	3.05 M	5.44 K	-14 K	-601 K	128 K

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
3.05 M	-601 K	335 K

Quarterly Interest Expense Akari Therapeutics, Plc

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
100 K	-	-	-	-	51 K	-2 K	-	-22 K	-13 K	-11 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.05 M	2.61 K	4.56 K	-	2.88 K	101 K	143 K	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
3.05 M	-22 K	284 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Aquestive Therapeutics AQST	6.55 M	$ 4.14	0.36 %	$ 443 M	USA
Arcturus Therapeutics Holdings ARCT	10.1 M	$ 8.41	4.73 %	$ 230 M	Israel
Ardelyx ARDX	4.5 M	$ 6.06	1.94 %	$ 1.46 B	USA
Arcutis Biotherapeutics ARQT	443 K	$ 23.83	0.85 %	$ 3.03 B	USA
Aytu BioScience AYTU	-512 K	$ 2.65	-1.12 %	$ 16.6 M	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
BioCardia BCDA	3 K	$ 1.2	-0.04 %	$ 8 M	USA
BioCryst Pharmaceuticals BCRX	59.3 M	$ 9.6	6.37 %	$ 1.98 B	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Biohaven Pharmaceutical Holding Company Ltd. BHVN	-7.26 M	$ 9.48	-3.27 %	$ 613 M	USA
BioVie BIVI	4.3 M	$ 1.45	2.09 %	$ 2.14 M	USA
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
BioLineRx Ltd. BLRX	9.07 M	$ 2.32	4.98 %	$ 908 M	Israel
BioMarin Pharmaceutical BMRN	15.3 M	$ 56.49	1.78 %	$ 10.8 B	USA
BioNTech SE BNTX	14.2 M	$ 92.3	1.23 %	$ 27.2 B	Germany
Allena Pharmaceuticals ALNA	-38 K	-	3.16 %	$ 1.9 M	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	48 K	-	10.36 %	$ 9.8 M	USA
Anavex Life Sciences Corp. AVXL	4.68 M	$ 3.04	1.54 %	$ 259 M	USA
BioXcel Therapeutics BTAI	-3.52 M	$ 1.16	-2.12 %	$ 14.2 M	USA
Cabaletta Bio CABA	2 M	$ 3.2	7.94 %	$ 322 M	USA
Can-Fite BioPharma Ltd. CANF	227 K	$ 3.21	4.56 %	$ 6.98 B	Israel
Aravive ARAV	2.84 M	-	-13.39 %	$ 1.45 M	USA
Catalyst Biosciences CBIO	-1.5 M	$ 19.97	2.94 %	$ 1.78 B	USA
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
Codexis CDXS	-4.81 M	$ 1.97	7.97 %	$ 172 M	USA
Cerus Corporation CERS	3.02 M	$ 1.91	2.42 %	$ 364 M	USA
Cullinan Management CGEM	-443 K	$ 15.4	6.72 %	$ 928 M	USA
Coherus BioSciences CHRS	9 M	$ 1.75	0.87 %	$ 205 M	USA